Diabetes & Metabolism Journal

Response

Response: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711–7): Sung Hye Kong, Bo Kyung Koo, Min Kyong Moon; Diabetes Metab J. 2019;43(6):913-914. Published online December 26, 2019; DOI: https://doi.org/10.4093/dmj.2019.0149

3,232 View
43 Download
1 Web of Science

PDF PubReader

Short Communication

Clinical Diabetes & Therapeutics
Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus: Sung Hye Kong, Bo Kyung Koo, Min Kyong Moon; Diabetes Metab J. 2019;43(5):711-717. Published online March 20, 2019; DOI: https://doi.org/10.4093/dmj.2018.0208

4,019 View
63 Download
10 Web of Science
11 Crossref

Abstract PDF PubReader

Background

The study aimed to evaluate the effects of dapagliflozin and metformin on vascular endothelial function and renal injury markers.

Methods

This prospective, randomized, open-label, crossover study included drug-naïve patients with type 2 diabetes mellitus, who were randomized to receive 8 weeks of initial treatment using metformin or dapagliflozin and crossed over for another 8 weeks of treatment after a 1-week washout period. Systemic endothelial function was evaluated via the reactive hyperemic index (RHI).

Results

The 22 participants included 10 males (45.5%) and had a median age of 58 years. The RHI values were not significantly changed during both 8-week treatment periods and there was no significant difference between the treatments. Relative to the metformin group, 8 weeks of dapagliflozin treatment produced significantly higher median N-acetyl-beta-D-glucosaminidase levels (10.0 ng/mL [interquartile range (IQR), 6.8 to 12.1 ng/mL] vs. 5.6 ng/mL [IQR, 3.8 to 8.0 ng/mL], P=0.013). Only the dapagliflozin group exhibited improved homeostatic model assessment of insulin resistance and body weight, while serum ketone and β-hydroxybutyrate levels increased.

Conclusion

Dapagliflozin treatment did not affect systemic endothelial function or renal injury markers except N-acetyl-beta-D-glucosaminidase.

Citations

Citations to this article as recorded by

Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome
Konrad Urbanek, Donato Cappetta, Gabriella Bellocchio, Maria Antonietta Coppola, Paola Imbrici, Marialucia Telesca, Maria Donniacuo, Maria Antonietta Riemma, Elena Mele, Eleonora Cianflone, Silvio Naviglio, Elena Conte, Giulia Maria Camerino, Marco Mele,
Pharmacological Research.2023; 188: 106659. CrossRef
Novel use of structural equation modelling to examine diet and metabolic traits associated with microvascular endothelial dysfunction in middle-aged Chinese males: a cross-sectional study
Rujia Miao, Renhe Yu, Hui Zhou, Lei Liu, Ting Peng, Jiangang Wang
BMJ Open.2023; 13(9): e073357. CrossRef
Endothelial Dysfunction and Heart Failure with Preserved Ejection Fraction—An Updated Review of the Literature
Mariarosaria De Luca, Giulia Crisci, Giuseppe Armentaro, Sebastiano Cicco, Giovanni Talerico, Emanuele Bobbio, Lorena Lanzafame, Christopher G. Green, Abbie G. McLellan, Radek Debiec, Paolo Caferra, Roberto Scicali, Antonio Cannatà, Muhammad Zubair Israr,
Life.2023; 14(1): 30. CrossRef
Renoprotection by Dapagliflozin in a Non-Diabetic Model of Cardiorenal Syndrome
Konrad Urbanek, Donato Cappetta, Gabriella Bellocchio, Maria Antonietta Coppola, Paola Imbrici, Marialucia Telesca, Maria Donniacuo, Maria Antonietta Riemma, Eleonora Cianflone, Silvio Naviglio, Elena Conte, Giulia Maria Camerino, Marco Mele, Mariarosaria
SSRN Electronic Journal .2022;[Epub] CrossRef
Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus
Vaneza Lira W. Wolf, Ikaro Breder, Luiz Sérgio F. de Carvalho, Alexandre A. S. Soares, Riobaldo M. Cintra, Joaquim Barreto, Daniel B. Munhoz, Sheila T. Kimura-Medorima, Wilson Nadruz, Gil Guerra-Júnior, Thiago Quinaglia, Elza Muscelli, Andrei C. Sposito
Nutrition & Diabetes.2021;[Epub] CrossRef
Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure
Gloria M. Gager, Dirk von Lewinski, Harald Sourij, Bernd Jilma, Ceren Eyileten, Krzysztof Filipiak, Martin Hülsmann, Jacek Kubica, Marek Postula, Jolanta M. Siller-Matula
Biomedicine & Pharmacotherapy.2021; 143: 112169. CrossRef
Association of Circulating Ketone Bodies With Functional Outcomes After ST-Segment Elevation Myocardial Infarction
Marie-Sophie L.Y. de Koning, B. Daan Westenbrink, Solmaz Assa, Erwin Garcia, Margery A. Connelly, Dirk J. van Veldhuisen, Robin P.F. Dullaart, Erik Lipsic, Pim van der Harst
Journal of the American College of Cardiology.2021; 78(14): 1421. CrossRef
Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium‐glucose co‐transporter‐2 inhibitors
Dimitrios Patoulias, Christodoulos Papadopoulos, Konstantinos Stavropoulos, Ioanna Zografou, Michael Doumas, Asterios Karagiannis
The Journal of Clinical Hypertension.2020; 22(4): 562. CrossRef
Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes
Yehuda Handelsman
Advances in Therapy.2019; 36(10): 2567. CrossRef
Letter: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711–7)
Dimitrios Patoulias, Michael Doumas
Diabetes & Metabolism Journal.2019; 43(6): 906. CrossRef
Response: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711–7)
Sung Hye Kong, Bo Kyung Koo, Min Kyong Moon
Diabetes & Metabolism Journal.2019; 43(6): 913. CrossRef

Response

Response: Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2017;41:23-30): Sung Hye Kong, Bo Kyung Koo, Min Kyong Moon; Diabetes Metab J. 2017;41(2):152-153. Published online April 14, 2017; DOI: https://doi.org/10.4093/dmj.2017.41.2.152

3,397 View
37 Download
1 Web of Science
1 Crossref

PDF PubReader

Citations

Citations to this article as recorded by

Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J2019;43:582–9)
Tae Seo Sohn
Diabetes & Metabolism Journal.2019; 43(6): 909. CrossRef

Original Article

Clinical Care/Education
Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus: Sung Hye Kong, Bo Kyung Koo, Min Kyong Moon; Diabetes Metab J. 2017;41(1):23-30. Published online December 16, 2016; DOI: https://doi.org/10.4093/dmj.2017.41.1.23

5,108 View
87 Download
10 Web of Science
8 Crossref

Abstract PDF PubReader

Background

There has been evidences of ethnic differences in the low density lipoprotein cholesterol (LDL-C) lowering effect of statin. We aimed to evaluate the efficacy of moderate-intensity statins in the treatment of dyslipidemia among Korean patients with type 2 diabetes mellitus (T2DM).

Methods

We analyzed a retrospective cohort that consisted of Korean patients with T2DM aged 40 to 75 years who had been prescribed any of the moderate-intensity statins (atorvastatin 10 or 20 mg, rosuvastatin 5 or 10 mg, pitavastatin 2 mg, or pravastatin 40 mg). Among them, only patients with baseline lipid profiles before starting statin treatment were selected, and changes in their lipid profiles before and 6 months after statin therapy were analyzed.

Results

Following the first 6 months of therapy, the overall LDL-C reduction was −47.4% (interquartile range, −56.6% to −34.1%). In total, 92.1% of the participants achieved an LDL-C level of <100 mg/dL, 38.3% had a 30% to 50% reduction in their LDL-C levels, and 42.3% had a reduction in their LDL-C levels greater than 50%. The response rates of each drug for achieving a LDL-C level <100 mg/dL were 81.7%, 93.1%, 95.0%, 95.0%, 96.5%, and 91.7% for treatment with atorvastatin doses of 10 or 20 mg, rosuvastatin 5 or 10 mg, pitavastatin 2 mg, and pravastatin 40 mg, respectively.

Conclusion

In conclusion, the use of moderate-intensity statins reduced LDL-C levels less than 100 mg/dL in most of the Korean patients studied with T2DM. The efficacies of those statins were higher than expected in about 42% of Korean patients with T2DM.

Citations

Citations to this article as recorded by

Effect of combining evolocumab with statin on carotid intraplaque neovascularization in patients with premature coronary artery disease (EPOCH)
Yanyan Han, Ling Ren, Xiang Fei, Jingjing Wang, Tao Chen, Jun Guo, Qi Wang
Atherosclerosis.2024; 391: 117471. CrossRef
Impact of Plasma Exposure of Statins and Their Metabolites With Major Adverse Cardiovascular Events in Chinese Patients With Coronary Artery Disease
Xiao-hong Zhou, Li-yun Cai, Wei-Hua Lai, Xue Bai, Yi-bin Liu, Qian Zhu, Guo-dong He, Ji-Yan Chen, Min Huang, Zhi-ling Zhou, Shi-long Zhong
Frontiers in Pharmacology.2020;[Epub] CrossRef
Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia
Jaecheol Moon, Soyeon Yoo, Gwanpyo Koh, Kyung-Wan Min, Hyun Ho Shin
Journal of Lipid and Atherosclerosis.2020; 9(1): 162. CrossRef
Effects of lowest-dose vs. highest-dose pitavastatin on coronary neointimal hyperplasia at 12-month follow-up in type 2 diabetic patients with non-ST elevation acute coronary syndrome: an optical coherence tomography analysis
Jung Wook Lim, Han Saem Jeong, Soon Jun Hong, Hyo Jeong Kim, Young Chan Kim, Bong Gyun Kang, Su Min Jeon, Jae Young Cho, Seung Hoon Lee, Hyung Joon Joo, Jae Hyoung Park, Cheol Woong Yu
Heart and Vessels.2019; 34(1): 62. CrossRef
Effect of Statin Therapy on Outcomes of Patients With Acute Ischemic Stroke and Atrial Fibrillation
Kang‐Ho Choi, Woo‐Keun Seo, Man‐Seok Park, Joon‐Tae Kim, Jong‐Won Chung, Oh Young Bang, Gyeong‐Moon Kim, Tae‐Jin Song, Bum Joon Kim, Sung Hyuk Heo, Jin‐Man Jung, Kyung‐Mi Oh, Chi Kyung Kim, Sungwook Yu, Kwang‐Yeol Park, Jeong‐Min Kim, Jong‐Ho Park, Jay Ch
Journal of the American Heart Association.2019;[Epub] CrossRef
Moderate-intensity versus high-intensity statin therapy in Korean patients with angina undergoing percutaneous coronary intervention with drug-eluting stents: A propensity-score matching analysis
Mahn-Won Park, Gyung-Min Park, Seungbong Han, Yujin Yang, Yong-Giun Kim, Jae-Hyung Roh, Hyun Woo Park, Jon Suh, Young-Rak Cho, Ki-Bum Won, Soe Hee Ann, Shin-Jae Kim, Dae-Won Kim, Sung Ho Her, Sang-Gon Lee, George C.M. Siontis
PLOS ONE.2018; 13(12): e0207889. CrossRef
Letter: Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2017;41:23-30)
Jae-Han Jeon
Diabetes & Metabolism Journal.2017; 41(2): 150. CrossRef
Response: Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2017;41:23-30)
Sung Hye Kong, Bo Kyung Koo, Min Kyong Moon
Diabetes & Metabolism Journal.2017; 41(2): 152. CrossRef

First
Prev
Page of 1
Next
Last

Search